Abuse-deterrent fentanyl patch at Nutriband (NASDAQ: NTRB) targets $80M-$200M
Rhea-AI Filing Summary
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Peak annual U.S. sales potential: $80 million-$200 million
Patent countries: 46 countries
Brand Institute global drug name approval share: 75%
+1 more
4 metrics
Peak annual U.S. sales potential
$80 million-$200 million
Market analysis for abuse-deterrent fentanyl transdermal system
Patent countries
46 countries
AVERSA abuse-deterrent transdermal technology IP portfolio
Brand Institute global drug name approval share
75%
Share of drug name approvals globally over 20+ years
Brand Institute FDA name approvals in 2024
87%
Portion of FDA-approved names in 2024 attributed to Brand Institute
Key Terms
Regulation FD Disclosure, abuse deterrent fentanyl transdermal system, AVERSA™ abuse-deterrent transdermal technology, transdermal patches, +1 more
5 terms
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure. See attached press release"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
abuse deterrent fentanyl transdermal system medical
"lead product, an abuse deterrent fentanyl transdermal system"
AVERSA™ abuse-deterrent transdermal technology medical
"This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology"
transdermal patches medical
"incorporate aversive agents into transdermal patches to prevent the abuse"
forward-looking statements regulatory
"constitute “forward-looking statements” within the meaning of the Private Securities"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Nutriband (NTRB) announce about its lead fentanyl patch?
Nutriband announced it has selected a commercial worldwide brand name candidate for its lead abuse-deterrent fentanyl transdermal patch. The proposed name and labeling will be submitted to the FDA and other regulators for review and approval as product development continues.
How large could the market be for Nutriband (NTRB)’s abuse-deterrent fentanyl patch?
Nutriband reports that its abuse-deterrent fentanyl transdermal system has potential peak annual U.S. sales of $80 million to $200 million. This estimate comes from a market analysis and reflects expected demand for safer pain-management options in the fentanyl patch segment.
What technology underpins Nutriband (NTRB)’s abuse-deterrent fentanyl patch?
The patch uses Nutriband’s AVERSA™ abuse-deterrent transdermal technology, which incorporates aversive agents into patches to deter abuse, diversion, misuse, and accidental exposure. AVERSA™ aims to improve safety for drugs with abuse potential, such as fentanyl, while keeping them available for appropriate patients.
How extensive is the patent protection for Nutriband (NTRB)’s AVERSA™ technology?
Nutriband states that its AVERSA™ abuse-deterrent transdermal technology is protected by a broad international intellectual property portfolio. Patents have been issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Who is helping Nutriband (NTRB) develop the brand for its fentanyl patch?
Nutriband partnered with Brand Institute, Inc., described as a global leader in pharmaceutical and healthcare-related name development. Brand Institute is developing the worldwide commercial brand name and visual identity, while its subsidiary Drug Safety Institute provides regulatory naming expertise.
Is Nutriband (NTRB)’s abuse-deterrent fentanyl patch approved by the FDA?
The filing describes the fentanyl patch as a product under development, with the proposed brand name and labeling to be submitted to the FDA and other regulators. It does not state that the product has received marketing approval in the United States or elsewhere.